benchmark dose
Recently Published Documents


TOTAL DOCUMENTS

308
(FIVE YEARS 70)

H-INDEX

31
(FIVE YEARS 3)

2022 ◽  
pp. 112825
Author(s):  
Dragana Javorac ◽  
Simona Tatović ◽  
Milena Anđelković ◽  
Aleksandra Repić ◽  
Katarina Baralić ◽  
...  

Author(s):  
Marwa F. Gad ◽  
Abdel‐Tawab H. Mossa ◽  
Amel A. Refaie ◽  
Noha E. Ibrahim ◽  
Samia M. M. Mohafrash

2021 ◽  
Vol 156 ◽  
pp. 106652
Author(s):  
Chu-Chih Chen ◽  
Yi-Chun Tsai ◽  
Yin-Han Wang ◽  
Chia-Fang Wu ◽  
Yi-Wen Chiu ◽  
...  

Author(s):  
Antero Vieira Silva ◽  
Joakim Ringblom ◽  
Peter Moldeus ◽  
Elin Törnqvist ◽  
Mattias Öberg

2021 ◽  
pp. 118103
Author(s):  
Dragana Javorac ◽  
Biljana Antonijević ◽  
Milena Anđelković ◽  
Aleksandra Repić ◽  
Petar Bulat ◽  
...  

Author(s):  
Alper James G. Alcaraz ◽  
Kamil Mikulášek ◽  
David Potěšil ◽  
Bradley Park ◽  
Kamran Shekh ◽  
...  
Keyword(s):  

2021 ◽  
Vol 3 ◽  
Author(s):  
Monika Batke ◽  
Fatemeh Moradi Afrapoli ◽  
Rupert Kellner ◽  
James F. Rathman ◽  
Chihae Yang ◽  
...  

The Threshold of Toxicological Concern (TTC) concept can be applied to organic compounds with the known chemical structure to derive a threshold for exposure, below which a toxic effect on human health by the compound is not expected. The TTC concept distinguishes between carcinogens that may act as genotoxic and non-genotoxic compounds. A positive prediction of a genotoxic mode of action, either by structural alerts or experimental data, leads to the application of the threshold value for genotoxic compounds. Non-genotoxic substances are assigned to the TTC value of their respective Cramer class, even though it is recognized that they could test positive in a rodent cancer bioassay. This study investigated the applicability of the Cramer classes specifically to provide adequate protection for non-genotoxic carcinogens. For this purpose, benchmark dose levels based on tumor incidence were compared with no observed effect levels (NOELs) derived from non-, pre- or neoplastic lesions. One key aspect was the categorization of compounds as non-genotoxic carcinogens. The recently finished CEFIC LRI project B18 classified the carcinogens of the Carcinogenicity Potency DataBase (CPDB) as either non-genotoxic or genotoxic compounds based on experimental or in silico data. A detailed consistency check resulted in a dataset of 137 non-genotoxic organic compounds. For these 137 compounds, NOEL values were derived from high quality animal studies with oral exposure and chronic duration using well-known repositories, such as RepDose, ToxRef, and COSMOS DB. Further, an effective tumor dose (ETD10) was calculated and compared with the lower confidence limit on benchmark dose levels (BMDL10) derived by model averaging. Comparative analysis of NOEL/EDT10/BMDL10 values showed that potentially bioaccumulative compounds in humans, as well as steroids, which both belong to the exclusion categories, occur predominantly in the region of the fifth percentiles of the distributions. Excluding these 25 compounds resulted in significantly higher but comparable fifth percentile chronic NOEL and BMDL10 values, while the fifth percentile EDT10 value was slightly higher but not statistically significant. The comparison of the obtained distributions of NOELs with the existing Cramer classes and their derived TTC values supports the application of Cramer class thresholds to all non-genotoxic compounds, such as non-genotoxic carcinogens.


Sign in / Sign up

Export Citation Format

Share Document